Biodesix, Inc. announced that new data will be presented at the 2024 American Thoracic Society (ATS) International Conference in San Diego, California. The presentation, titled "Performance comparison of a blood-based integrated classifier for lung nodule risk stratification in patients with versus without emphysema, " will be presented by Arthur Romero MD, MSC, FCCP, Associate Professor of Pulmonary and Critical Care Medicine at the University of Nevada Las Vegas. Emphysema is a common comorbid pulmonary condition in patients with lung nodules and presents unique diagnostic and treatment challenges.

The presentation will review a subgroup analysis of 280 patients enrolled in the prospective, real-world ORACLE study (NCT03766958), demonstrating that the Nodify XL2 test has high negative predictive value, or true negative rate, in patients with and without emphysema. These results suggest that the test can assist with ruling out lung cancer regardless of a patient?s emphysema status.